Information Hub

Clinical News

2018-08-01

Is Immunotherapy Right for Me?

Cancer immunotherapy has been hailed as the most promising treatment against cancer in recent decades, but what exactly is immunotherapy? Is Immunotherapy right for me?

Source:

2018-07-25

Trastuzumab deruxtecan Impresses in HER2-Expressing Gastric Cancer

According to an ongoing phase I trial presented at the ASCO 2018 Annual Meeting, Trastuzumab deruxtecan (DS-8201a) demonstrated promising efficacy in heavily pretreated subjects with HER2-expressing gastric cancer.

Source:

Journal of Clinical Oncology 2018 36:4_suppl, 118-118

2018-07-25

LOXO-292 Phase I Results Show Promise in RET-Positive Tumors

According to findings from the phase I LIBRETTO-001 study presented at the 2018 ASCO Annual Meeting, LOXO-292 demonstrated impressive clinical efficacy across RET-altered solid tumors.

Source:

J Clin Oncol. 2018;36 (suppl; abstr 102)

2018-07-25

FDA Approves The Combination of Encorafenib (Braftovi) and Binimetinib (Mektovi) for BRAF-mutant Melanoma

The U.S. FDA approves Encorafenib plus Binimetinib in combination for patients with BRAFV600-mutant melanoma based on the phase III COLUMBUS trial.

Source:

Dummer R, et al. Lancet Oncol. 2018 May;19(5):603-615.

2018-07-25

TAS-120 Shows Clinical Benefit in Patients with Cholangiocarcinoma Harboring FGFR2 Gene Fusions

A pan-FGFR tyrosine kinase inhibitor, TAS-120, shows significant effect in cholangiocarcinoma patients with FGFR2 gene fusion.

Source:

Meric-Bernstam F, et al. Ann Oncol. 2018;29 (suppl 5; abstr O-001)

2018-07-25

Germline Mutation in ATM, BRCA1, BRCA2, CDKN2A, MLH1 and TP53 are Associated with Pancreatic Cancer

Mayo clinic enrolled 3030 cases with pancreatic cancer from 2000 to 2016, and identified 21 cancer predisposition genes. The test results were then compared with controls from gnomAD and ExAC database. From this case-control study, mutations in those 6 ge

Source:

JAMA. 2018;319(23):2401-2409

2018-07-01

FDA grants talazoparib priority review for BRCA+ breast cancer

The FDA has accepted the NDA and granted priority review for talazoparib (PARP inhibitor, Pfizer) for the treatment of patients with germline BRCA mutation-positive, HER2-negative locally advanced or metastatic breast cancer based on data from the EMBRACA

Source:

AACR Journal

2018-07-01

Combination of Bevacizumab and Erlotinib prolongs PFS in patients with EGFR-mutated NSCLC

III NEJ026 trial showed clinical benefit with combination of Bevacizumab and Erlotinib in patients with with EGFR-mutated NSCLC.

Source:

ASCO

2018-07-01

Next-Generation Sequencing found to be most cost-effective in metastatic NSCLC

Next-generation sequencing (NGS) in metastatic NSCLC can save substantial savings compared to other strategies, according to a study presented at the 2018 ASCO Annual Meeting.

Source:

Clin Oncol

2018-07-01

Blood test may help detect early-stage lung cancer

Preliminary results from the Circulating Cell-Free Genome Atlas (CCGA) study suggest that cell-free DNA (cfDNA) tests could detect early-stage lung cancer with low rates of false-positive results.

Source:

Clin Oncol